Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
A total of 100 women who were using depot medroxyprogesterone acetate (DMPA) for contraception and who had experienced at least 6 months of drug induced amenorrhea, were randomized to either switching their method of contraception to Cyclofem, or continuing with DMPA. At the end of 6 months, 82% of the Cyclofem users had experienced some vaginal bleeding, compared with 10% of DMPA users. Time to resumption of vaginal bleeding was related to the duration of DMPA use to the duration of DMPA induced amenorrhea, and to the body mass index of the user. Over the 6 months of follow-up, 94% of Cyclofem users complained of some side effects, compared with 22% of DMPA users. The most frequently cited problems among Cyclofem users included breast tenderness, abdominal pain, and dysmenorrhea; yet a third of these women opted to stay on Cyclofem at the end of the study. It is concluded that switching to Cyclofem is a new option for DMPA users who are concerned about amenorrhea. Although using Cyclofem in this setting will not meet the needs of all such women, its effectiveness in inducing vaginal bleeding justifies a trial in those who have no contraindication to estrogen treatment.
Piya-Anant
M
M
Siriraj Family Health Research Centre, Department of Obstetrics and Gynecology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Koetsawang
S
S
Patrasupapong
N
N
Dinchuen
P
P
d'Arcangues
C
C
Piaggio
G
G
Pinol
A
A
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000188:drug therapy*; D015331:Cohort Studies; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D010352:Patient Dropouts; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors; D014592:Uterine Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D045167:Progesterone Congeners; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate